| Company Name: |
Biolab Reagents Gold |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | Faricimab Basic information |
| Product Name: | Faricimab | | Synonyms: | Faricimab;Research Grade Faricimab (DHA42301);Research Grade Faricimab | | CAS: | 1607793-29-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Faricimab Structure]() |
| | Faricimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Faricimab Usage And Synthesis |
| Uses | Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO)[1][2][3][4][5]. | | in vivo | Faricimab (10 mg/kg, i.p., twice interval 1 week for 1 or 5 weeks) reduces spontaneous choroidal neovascularization (sCNV), lesion leakage area and subretinal Iba1+, CD11b+, and CD45+ cell infiltration in JR5558 mice[4].
Faricimab (3 μg/μL, intravitreal injections, a single dose for 48 h) prevents ischemia/reperfusion (I/R) injury-induced retinal permeability and cell death in retinal I/R injury mouse model[4].
| Animal Model: | Retinal I/R injury mouse model[4] | | Dosage: | 3 μg/μL | | Administration: | intravitreal injections, a single dose for 48 h | | Result: | Significantly reduced retinal vascular permeability (by 64%) and cell death compared with IgG control-treated mice. |
| Animal Model: | JR5558 mice[4] | | Dosage: | 10 mg/kg | | Administration: | i.p., twice interval 1 week for 1 or 5 weeks | | Result: | Might promote vascular stability by inhibiting neovascularization and subsequent neovascular leakage and decreased immune cell accumulation associated with sCNV lesions in JR5558 mice. |
| | References | [1] Sahni J, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 Aug;126(8):1155-1170. DOI:10.1016/j.ophtha.2019.03.023
[2] Nicolò M, et al. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases[J]. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. DOI:10.1080/13543784.2021.1879791
[3] Penha FM, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME[J]. Int J Retina Vitreous. 2024 Jan 17;10(1):5. DOI:10.1186/s40942-024-00525-9
[4] Canonica J, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion[J]. Front Cell Neurosci. 2023 Jun 12;17:1192464. DOI:10.3389/fncel.2023.1192464
[5] Jrstad K, et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties[J]. Int J Retina Vitreous. 2023 Nov 7;9(1):65. DOI:10.1186/s40942-023-00507-3 |
| | Faricimab Preparation Products And Raw materials |
|